메뉴 건너뛰기




Volumn 7, Issue 6, 2011, Pages 689-698

Use of bone turnover markers in clinical osteoporosis assessment in women: Current issues and future options

Author keywords

bone quality; bone turnover marker; fracture; prediction; women

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; AMG 785; AMINO TERMINAL TELOPEPTIDE; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; DENOSUMAB; GLUCAGON LIKE PEPTIDE 2; IBANDRONIC ACID; ODANACATIB; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROTEIN ANTIBODY; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

EID: 80155142307     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.74     Document Type: Review
Times cited : (27)

References (108)
  • 1
    • 67349277390 scopus 로고    scopus 로고
    • Local communication on and within bone controls bone remodeling
    • Henriksen K, Neutzsky-Wulff AV, Bonewald LF et al. Local communication on and within bone controls bone remodeling. Bone 44, 1026-1033 (2009).
    • (2009) Bone , vol.44 , pp. 1026-1033
    • Henriksen, K.1    Neutzsky-Wulff, A.V.2    Bonewald, L.F.3
  • 2
    • 33646889773 scopus 로고    scopus 로고
    • Bone quality - The material and structural basis of bone strength and fragility
    • Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250-2261 (2006).
    • (2006) N. Engl. J. Med , vol.354 , pp. 2250-2261
    • Seeman, E.1    Delmas, P.D.2
  • 3
    • 79951655957 scopus 로고    scopus 로고
    • Osteoclast activity and subtypes as a function of physiology and pathology - Implications for future treatments of osteoporosis
    • Henriksen K, Bollerslev J, Everts V et al. Osteoclast activity and subtypes as a function of physiology and pathology - implications for future treatments of osteoporosis. Endocr. Rev. 32, 31-63 (2011).
    • (2011) Endocr. Rev. , vol.32 , pp. 31-63
    • Henriksen, K.1    Bollerslev, J.2    Everts, V.3
  • 5
    • 33846332080 scopus 로고    scopus 로고
    • New mechanisms and targets in the treatment of bone fragility
    • DOI 10.1042/CS20060046
    • Martin TJ, Seeman E. New mechanisms and targets in the treatment of bone fragility. Clin. Sci. [Lond.] 112, 77-91 (2007). (Pubitemid 46120088)
    • (2007) Clinical Science , vol.112 , Issue.1-2 , pp. 77-91
    • Martin, T.J.1    Seeman, E.2
  • 6
    • 38949204304 scopus 로고    scopus 로고
    • Pathogenesis of postmenopausal osteoporosis
    • Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA
    • Eastell R. Pathogenesis of postmenopausal osteoporosis. In:Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition). Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA, 259-262 (2006).
    • (2006) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition) , pp. 259-262
    • Eastell, R.1
  • 8
    • 79960621438 scopus 로고    scopus 로고
    • The WHO absolute fracture risk models [FRAX®]: Do clinical risk factors improve fracture prediction in older women without osteoporosis?
    • Hillier TA, Cauley JA, Rizzo JH et al. The WHO absolute fracture risk models [FRAX®]: do clinical risk factors improve fracture prediction in older women without osteoporosis? J. Bone Miner. Res. 26, 1774-1782 (2011).
    • (2011) J. Bone Miner. Res. , vol.26 , pp. 1774-1782
    • Hillier, T.A.1    Cauley, J.A.2    Rizzo, J.H.3
  • 9
    • 79960915428 scopus 로고    scopus 로고
    • Official positions for FRAX clinical regarding biochemical markers from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on FRAX
    • McCloskey EV, Vasikaran S, Cooper C. Official positions for FRAX clinical regarding biochemical markers from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on FRAX. J. Clin. Densitom. 14, 220-222 (2011).
    • (2011) J. Clin. Densitom. , vol.14 , pp. 220-222
    • McCloskey, E.V.1    Vasikaran, S.2    Cooper, C.3
  • 10
    • 66149103673 scopus 로고    scopus 로고
    • Biochemical markers and the FDA critical path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development
    • Karsdal MA, Henriksen K, Leeming DJ et al. Biochemical markers and the FDA critical path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14, 181-202 (2009).
    • (2009) Biomarkers , vol.14 , pp. 181-202
    • Ma, K.1    Henriksen, K.2    Leeming, D.J.3
  • 13
    • 0030893199 scopus 로고    scopus 로고
    • Hormone replacement therapy in the prevention and treatment of osteoporosis
    • Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporos. Int. 7(Suppl. 1), S3-S7 (1997
    • (1997) Osteoporos. Int. , vol.7 , Issue.SUPPL. 1
    • Delmas, P.D.1
  • 15
    • 78651493109 scopus 로고    scopus 로고
    • Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards
    • Vasikaran S, Eastell R, Bruyere O et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22, 391-420 (2011).
    • (2011) Osteoporos. Int. , vol.22 , pp. 391-420
    • Vasikaran, S.1    Eastell, R.2    Bruyere, O.3
  • 17
    • 0034141218 scopus 로고    scopus 로고
    • Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: A biological clock of protein aging with clinical potential
    • DOI 10.1042/0264-6021:3450473
    • Cloos PA, Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem. J. 345(Pt 3), 473-480 (2000). (Pubitemid 30099075)
    • (2000) Biochemical Journal , vol.345 , Issue.3 , pp. 473-480
    • Cloos, P.A.C.1    Fledelius, C.2
  • 18
    • 1642422776 scopus 로고    scopus 로고
    • Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline
    • DOI 10.1007/s00774-003-0460-4
    • Okabe R, Inaba M, Nakatsuka K et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J. Bone Miner. Metab. 22, 127-131 (2004). (Pubitemid 38405041)
    • (2004) Journal of Bone and Mineral Metabolism , vol.22 , Issue.2 , pp. 127-131
    • Okabe, R.1    Inaba, M.2    Nakatsuka, K.3    Miki, T.4    Naka, H.5    Moriguchi, A.6    Nishizawa, Y.7
  • 20
    • 1842739009 scopus 로고    scopus 로고
    • Possibilities of monitoring bone metabolism in ruminants - An overview of the methods in use
    • Liesegang A. Possibilities of monitoring bone metabolism in ruminants: an overview of the methods in use. Acta Vet. Scand. Suppl. 97, 23-28 (2003). (Pubitemid 38469650)
    • (2003) Acta Veterinaria Scandinavica, Supplement , Issue.97 , pp. 23-28
    • Liesegang, A.1
  • 21
    • 33645457788 scopus 로고    scopus 로고
    • The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients
    • Leeming DJ, Koizumi M, Byrjalsen I et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 15, 32-38 (2006).
    • (2006) Cancer Epidemiol. Biomarkers Prev. , vol.15 , pp. 32-38
    • Leeming, D.J.1    Koizumi, M.2    Byrjalsen, I.3
  • 22
    • 34047185276 scopus 로고    scopus 로고
    • Assessment of osteoclast number and function: Application in the development of new and improved treatment modalities for bone diseases
    • DOI 10.1007/s00198-006-0286-8
    • Henriksen K, Tanko LB, Qvist P et al. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos. Int. 18, 681-685 (2007). (Pubitemid 46525540)
    • (2007) Osteoporosis International , vol.18 , Issue.5 , pp. 681-685
    • Henriksen, K.1    Tanko, L.B.2    Qvist, P.3    Delmas, P.D.4    Christiansen, C.5    Karsdal, M.A.6
  • 23
    • 70350591051 scopus 로고    scopus 로고
    • Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate
    • Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas 64, 188-192 (2009).
    • (2009) Maturitas , vol.64 , pp. 188-192
    • Munoz-Torres, M.1    Reyes-Garcia, R.2    Mezquita-Raya, P.3
  • 24
    • 79960397931 scopus 로고    scopus 로고
    • Procollagen type i N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats
    • Veidal SS, Vassiliadis E, Bay-Jensen AC et al. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 3, 5 (2010).
    • Fibrogenesis Tissue Repair , vol.3 , Issue.5 , pp. 2010
    • Veidal, S.S.1    Vassiliadis, E.2    Bay-Jensen, A.C.3
  • 25
    • 84856639090 scopus 로고    scopus 로고
    • Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients
    • DOI: 10.1093/ndt/ gfr270 Epub ahead of print
    • Cejka D, Jager-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol. Dial. Transplant DOI: 10.1093/ndt/ gfr270 (2011) (Epub ahead of print).
    • (2011) Nephrol. Dial. Transplant
    • Cejka, D.1    Jager-Lansky, A.2    Kieweg, H.3
  • 26
    • 80155124726 scopus 로고    scopus 로고
    • Acute decline in serum sclerostin in response to PTH infusion in healthy men
    • DOI: 10.1210/jc.2011-1534 Epub ahead of print
    • Yu EW, Kumbhani R, Siwila-Sackman E et al. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J. Clin. Endocrinol. Metab. DOI: 10.1210/jc.2011- 1534 (2011) (Epub ahead of print).
    • (2011) J. Clin. Endocrinol. Metab.
    • Yu, E.W.1    Kumbhani, R.2    Siwila-Sackman, E.3
  • 27
    • 77957846460 scopus 로고    scopus 로고
    • Relation of age, gender, and bone mass to circulating sclerostin levels in women and men
    • Modder UI, Hoey KA, Amin S et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J. Bone Miner. Res. 26, 373-379 (2011).
    • (2011) J. Bone Miner. Res. , vol.26 , pp. 373-379
    • Modder, U.I.1    Hoey, K.A.2    Amin, S.3
  • 28
    • 79251589954 scopus 로고    scopus 로고
    • The role of Dkk1 in bone mass regulation: Correlating serum Dkk1 expression with bone mineral density
    • Butler JS, Murray DW, Hurson CJ et al. The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J. Orthop. Res. 29, 414-418 (2011).
    • (2011) J. Orthop. Res. , vol.29 , pp. 414-418
    • Butler, J.S.1    Murray, D.W.2    Hurson, C.J.3
  • 30
    • 0034526238 scopus 로고    scopus 로고
    • Prediction of bone loss in postmenopausal women
    • DOI 10.1007/s001980070005
    • Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporos. Int. 11(Suppl. 6), S45-S54 (2000). (Pubitemid 32039512)
    • (2000) Osteoporosis International , vol.11 , Issue.SUPPL. 6
    • Stepan, J.J.1
  • 31
    • 0034526072 scopus 로고    scopus 로고
    • The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation
    • Delmas PD, Eastell R, Garnero P et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation. Osteoporos. Int. 11(Suppl. 6), S2-S17 (2000).
    • (2000) Osteoporos. Int. , vol.11 , Issue.SUPPL. 6
    • Delmas, P.D.1    Eastell, R.2    Garnero, P.3
  • 35
    • 1642367713 scopus 로고    scopus 로고
    • Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study
    • DOI 10.1016/j.bone.2003.12.021, PII S8756328203004794
    • Bagger YZ, Tanko LB, Alexandersen P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34, 728-735 (2004). (Pubitemid 38393810)
    • (2004) Bone , vol.34 , Issue.4 , pp. 728-735
    • Bagger, Y.Z.1    Tanko, L.B.2    Alexandersen, P.3    Hansen, H.B.4    Mollgaard, A.5    Ravn, P.6    Qvist, P.7    Kanis, J.A.8    Christiansen, C.9
  • 38
    • 0343517092 scopus 로고    scopus 로고
    • Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study
    • Garnero P, Sornay-Rendu E, Claustrat B et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone Miner. Res. 15, 1526-1536 (2000). (Pubitemid 30484522)
    • (2000) Journal of Bone and Mineral Research , vol.15 , Issue.8 , pp. 1526-1536
    • Patrick, G.1    Sornay-Rendu, E.2    Claustrat, B.3    Delmas, P.D.4
  • 40
    • 0031698795 scopus 로고    scopus 로고
    • Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study
    • DOI 10.1007/s001980050100
    • Garnero P, Dargent-Molina P, Hans D et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos. Int. 8, 563-569 (1998). (Pubitemid 28566972)
    • (1998) Osteoporosis International , vol.8 , Issue.6 , pp. 563-569
    • Garnero, P.1    Dargent-Molina, P.2    Hans, D.3    Schott, A.M.4    Breart, G.5    Meunier, P.J.6    Delmas, P.D.7
  • 41
    • 0037466335 scopus 로고    scopus 로고
    • Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women
    • DOI 10.1016/S0378-5122(03)00042-2
    • Bruyere O, Collette J, Delmas P et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44, 259-265 (2003). (Pubitemid 36412177)
    • (2003) Maturitas , vol.44 , Issue.4 , pp. 259-265
    • Bruyere, O.1    Collette, J.2    Delmas, P.3    Rouillon, A.4    Roux, C.5    Seidel, L.6    Richy, F.7    Reginster, J.-Y.8
  • 44
    • 78049522060 scopus 로고    scopus 로고
    • Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect
    • Eisman JA, Bone HG, Hosking DJ et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242-251 (2010).
    • (2010) J. Bone Miner. Res. , vol.26 , pp. 242-251
    • Eisman, J.A.1    Bone, H.G.2    Hosking, D.J.3
  • 45
    • 79951615188 scopus 로고    scopus 로고
    • Lessons learned from the development of oral calcitonin: The first tablet formulation of a peptide in Phase III clinical trials
    • Karsdal MA, Henriksen K, Bay-Jensen AC et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a peptide in Phase III clinical trials. J. Clin. Pharmacol. 51, 460-471 (2010).
    • (2010) J. Clin. Pharmacol. , vol.51 , pp. 460-471
    • Ma, K.1    Henriksen, K.2    Bay-Jensen, A.C.3
  • 46
    • 78650958526 scopus 로고    scopus 로고
    • Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
    • Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19-26 (2011).
    • (2011) J. Bone Miner. Res. , vol.26 , pp. 19-26
    • Padhi, D.1    Jang, G.2    Stouch, B.3    Fang, L.4    Posvar, E.5
  • 48
    • 77953433829 scopus 로고    scopus 로고
    • Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase i trial
    • Hannon RA, Clack G, Rimmer M et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase I trial. J. Bone Miner. Res. 25, 463-471 (2010
    • (2010) J. Bone Miner. Res. , vol.25 , pp. 463-471
    • Hannon, R.A.1    Clack, G.2    Rimmer, M.3
  • 51
    • 0033829969 scopus 로고    scopus 로고
    • A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
    • PROOF study group
    • Chesnut CH 3rd, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am. J. Med. 109, 267-276 (2000).
    • (2000) Am. J. Med. , vol.109 , pp. 267-276
    • Chesnut III, C.H.1    Silverman, S.2    Andriano, K.3
  • 53
    • 0942300651 scopus 로고    scopus 로고
    • Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption
    • DOI 10.1016/j.bone.2003.04.002
    • Hannon RA, Clowes JA, Eagleton AC et al. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34, 187-194 (2004). (Pubitemid 38142448)
    • (2004) Bone , vol.34 , Issue.1 , pp. 187-194
    • Hannon, R.A.1    Clowes, J.A.2    Eagleton, A.C.3    Al Hadari, A.4    Eastell, R.5    Blumsohn, A.6
  • 55
    • 65549105437 scopus 로고    scopus 로고
    • Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study
    • Emkey R, Delmas PD, Bolognese M et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clin. Ther. 31, 751-761 (2009).
    • (2009) Clin. Ther. , vol.31 , pp. 751-761
    • Emkey, R.1    Delmas, P.D.2    Bolognese, M.3
  • 60
    • 69049083492 scopus 로고    scopus 로고
    • Denosumab for prevention of fractures in postmenopausal women with osteoporosis
    • Cummings SR, San MJ, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
    • (2009) N. Engl. J. Med. , vol.361 , pp. 756-765
    • Cummings, S.R.1    San, M.J.2    McClung, M.R.3
  • 62
    • 79951746928 scopus 로고    scopus 로고
    • Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
    • Eastell R, Christiansen C, Grauer A et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 530-537 (2010).
    • (2010) J. Bone Miner. Res. , vol.26 , pp. 530-537
    • Eastell, R.1    Christiansen, C.2    Grauer, A.3
  • 63
    • 0036635349 scopus 로고    scopus 로고
    • The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women
    • DOI 10.1111/j.1471-0528.2002.01177.x, PII S1470032802011771
    • Pereda CA, Hannon RA, Naylor KE et al. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women. BJOG 109, 812-820 (2002). (Pubitemid 37329258)
    • (2002) BJOG: An International Journal of Obstetrics and Gynaecology , vol.109 , Issue.7 , pp. 812-820
    • Pereda, C.A.1    Hannon, R.A.2    Naylor, K.E.3    Eastell, R.4
  • 64
    • 77649187377 scopus 로고    scopus 로고
    • The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women
    • Naylor KE, Clowes JA, Finigan J et al. The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 46, 592-597 (2010).
    • (2010) Bone , vol.46 , pp. 592-597
    • Naylor, K.E.1    Clowes, J.A.2    Finigan, J.3
  • 68
    • 80052337245 scopus 로고    scopus 로고
    • The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: Results of a randomized, open-label clinical trial
    • Quesada-Gomez JM, Muschitz C, Gomez-Reino J et al. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial. Osteoporos. Int. 22, 2529-2537 (2010).
    • (2010) Osteoporos. Int. , vol.22 , pp. 2529-2537
    • Quesada-Gomez, J.M.1    Muschitz, C.2    Gomez-Reino, J.3
  • 69
    • 77953510486 scopus 로고    scopus 로고
    • Odanacatib, a cathepsin K inhibitor for osteoporosis: A 2 year study in postmenopausal women with low bone density
    • Bone HG, McClung MR, Roux C et al. Odanacatib, a cathepsin K inhibitor for osteoporosis: a 2 year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937-947 (2009).
    • (2009) J. Bone Miner. Res. , vol.25 , pp. 937-947
    • Bone, H.G.1    McClung, M.R.2    Roux, C.3
  • 70
    • 79958803353 scopus 로고    scopus 로고
    • Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study
    • Eastell R, Nagase S, Ohyama M et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. J. Bone Miner. Res. 26, 1303-1312 (2011).
    • (2011) J. Bone Miner. Res. , vol.26 , pp. 1303-1312
    • Eastell, R.1    Nagase, S.2    Ohyama, M.3
  • 71
    • 70349279885 scopus 로고    scopus 로고
    • Four-month treatment with GLP-2 significantly increases hip BMD: A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
    • Henriksen DB, Alexandersen P, Hartmann B et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45, 833-842 (2009).
    • (2009) Bone , vol.45 , pp. 833-842
    • Henriksen, D.B.1    Alexandersen, P.2    Hartmann, B.3
  • 72
    • 70350230386 scopus 로고    scopus 로고
    • Rapid and robust response of biochemical markers of bone formation to teriparatide therapy
    • Glover SJ, Eastell R, McCloskey EV et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45, 1053-1058 (2009).
    • (2009) Bone , vol.45 , pp. 1053-1058
    • Glover, S.J.1    Eastell, R.2    McCloskey, E.V.3
  • 75
    • 0034519794 scopus 로고    scopus 로고
    • Preanalytical variability of biochemical markers of bone turnover
    • DOI 10.1007/s001980070004
    • Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 11(Suppl. 6), S30-S44 (2000). (Pubitemid 32039511)
    • (2000) Osteoporosis International , vol.11 , Issue.SUPPL. 6
    • Hannon, R.1    Eastell, R.2
  • 76
    • 0043125769 scopus 로고    scopus 로고
    • Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis
    • DOI 10.1016/S8756-3282(03)00168-6
    • Ravn P, Thompson DE, Ross PD et al. Biochemical markers for prediction of 4 year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33, 150-158 (2003). (Pubitemid 36957958)
    • (2003) Bone , vol.33 , Issue.1 , pp. 150-158
    • Ravn, P.1    Thompson, D.E.2    Ross, P.D.3    Christiansen, C.4
  • 79
    • 0035664686 scopus 로고    scopus 로고
    • Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis
    • DOI 10.1007/s001980170020
    • Bjarnason NH, Sarkar S, Duong T et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos. Int. 12, 922-930 (2001). (Pubitemid 34001005)
    • (2001) Osteoporosis International , vol.12 , Issue.11 , pp. 922-930
    • Bjarnason, N.H.1    Sarkar, S.2    Duong, T.3    Mitlak, B.4    Delmas, P.D.5    Christiansen, C.6
  • 81
    • 77954565409 scopus 로고    scopus 로고
    • Relationship between 3 month changes in biochemical markers of bone remodeling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years
    • Bruyere O, Collette J, Rizzoli R et al. Relationship between 3 month changes in biochemical markers of bone remodeling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos. Int. 21, 1031-1036 (2009).
    • (2009) Osteoporos. Int. , vol.21 , pp. 1031-1036
    • Bruyere, O.1    Collette, J.2    Rizzoli, R.3
  • 82
  • 83
    • 77953433829 scopus 로고    scopus 로고
    • Effects of the src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase i trial
    • Hannon RA, Clack G, Rimmer M et al. Effects of the src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase I trial. J. Bone Miner. Res. 25, 463-471 (2010).
    • (2010) J. Bone Miner. Res. , vol.25 , pp. 463-471
    • Hannon, R.A.1    Clack, G.2    Rimmer, M.3
  • 84
    • 0036309083 scopus 로고    scopus 로고
    • Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting
    • DOI 10.1016/S8756-3282(02)00791-3, PII S8756328202007913
    • Qvist P, Christgau S, Pedersen BJ et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31, 57-61 (2002). (Pubitemid 34754426)
    • (2002) Bone , vol.31 , Issue.1 , pp. 57-61
    • Qvist, P.1    Christgau, S.2    Pedersen, B.J.3    Schlemmer, A.4    Christiansen, C.5
  • 85
    • 52949084000 scopus 로고    scopus 로고
    • Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of salmon calcitonin
    • Karsdal MA, Byrjalsen I, Riis BJ et al. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin. Pharmacol. 8, 5 (2008).
    • (2008) BMC Clin. Pharmacol. , vol.8 , pp. 5
    • Ma, K.1    Byrjalsen, I.2    Riis, B.J.3
  • 86
    • 58149327054 scopus 로고    scopus 로고
    • Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin
    • Karsdal MA, Byrjalsen I, Riis BJ et al. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin. Pharmacol. 8, 12 (2008).
    • (2008) BMC Clin. Pharmacol. , vol.8 , pp. 12
    • Ma, K.1    Byrjalsen, I.2    Riis, B.J.3
  • 87
    • 58849158708 scopus 로고    scopus 로고
    • A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin
    • Karsdal MA, Byrjalsen I, Henriksen K et al. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J. Clin. Pharmacol. 49, 229-234 (2009).
    • (2009) J. Clin. Pharmacol. , vol.49 , pp. 229-234
    • Ma, K.1    Byrjalsen, I.2    Henriksen, K.3
  • 88
    • 63849211819 scopus 로고    scopus 로고
    • Influence of food intake on the bioavailability and efficacy of oral calcitonin
    • Karsdal MA, Byrjalsen I, Azria M et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br. J. Clin. Pharmacol. 67, 413-420 (2009).
    • (2009) Br. J. Clin. Pharmacol. , vol.67 , pp. 413-420
    • Ma, K.1    Byrjalsen, I.2    Azria, M.3
  • 89
    • 74149092299 scopus 로고    scopus 로고
    • The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: A 14 day randomized study
    • Karsdal MA, Byrjalsen I, Henriksen K et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14 day randomized study. Osteoarthritis Cartilage 18, 150-159 (2009).
    • (2009) Osteoarthritis Cartilage , vol.18 , pp. 150-159
    • Ma, K.1    Byrjalsen, I.2    Henriksen, K.3
  • 90
    • 76949084136 scopus 로고    scopus 로고
    • Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy
    • Karsdal MA, Byrjalsen I, Henriksen K et al. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur. J. Clin. Pharmacol. 66, 29-37 (2009).
    • (2009) Eur. J. Clin. Pharmacol. , vol.66 , pp. 29-37
    • Ma, K.1    Byrjalsen, I.2    Henriksen, K.3
  • 91
    • 0036233579 scopus 로고    scopus 로고
    • Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study
    • Garnero P, Cloos P, Sornay-Rendu E et al. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J. Bone Miner. Res. 17, 826-833 (2002). (Pubitemid 34441899)
    • (2002) Journal of Bone and Mineral Research , vol.17 , Issue.5 , pp. 826-833
    • Garnero, P.1    Cloos, P.2    Sornay-Rendu, E.3    Qvist, P.4    Delmas, P.D.5
  • 92
    • 0030999235 scopus 로고    scopus 로고
    • Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized ASP-GLY sequence within the C- terminal telopeptide (α1) region
    • DOI 10.1074/jbc.272.15.9755
    • Fledelius C, Johnsen AH, Cloos PA et al. Characterization of urinary degradation products derived from type I collagen. Identification of a b-isomerized Asp-Gly sequence within the C-terminal telopeptide (a1) region. J. Biol. Chem. 272, 9755-9763 (1997). (Pubitemid 27171639)
    • (1997) Journal of Biological Chemistry , vol.272 , Issue.15 , pp. 9755-9763
    • Fledelius, C.1    Johnsen, A.H.2    Cloos, P.A.C.3    Bonde, M.4    Qvist, P.5
  • 94
    • 38849202528 scopus 로고    scopus 로고
    • Bone turnover and bone collagen maturation in osteoporosis: Effects of antiresorptive therapies
    • DOI 10.1007/s00198-007-0462-5
    • Byrjalsen I, Leeming DJ, Qvist P et al. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos. Int. 19, 339-348 (2008). (Pubitemid 351199183)
    • (2008) Osteoporosis International , vol.19 , Issue.3 , pp. 339-348
    • Byrjalsen, I.1    Leeming, D.J.2    Qvist, P.3    Christiansen, C.4    Karsdal, M.A.5
  • 95
    • 49549092964 scopus 로고    scopus 로고
    • The effects of oral calcitonin on bone collagen maturation: Implications for bone turnover and quality
    • Karsdal MA, Byrjalsen I, Leeming DJ et al. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos. Int. 19, 1355-1361 (2008).
    • (2008) Osteoporos. Int. , vol.19 , pp. 1355-1361
    • Ma, K.1    Byrjalsen, I.2    Leeming, D.J.3
  • 96
    • 77953706518 scopus 로고    scopus 로고
    • Novel combinations of Post-Translational Modification [PTM] neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease?
    • Karsdal MA, Henriksen K, Leeming DJ et al. Novel combinations of Post-Translational Modification [PTM] neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin. Biochem. 43, 793-804 (2010).
    • (2010) Clin. Biochem. , vol.43 , pp. 793-804
    • Ma, K.1    Henriksen, K.2    Leeming, D.J.3
  • 97
    • 0026675759 scopus 로고
    • Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
    • Sell DR, Lapolla A, Odetti P et al. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41, 1286-1292 (1992).
    • (1992) Diabetes , vol.41 , pp. 1286-1292
    • Sell, D.R.1    Lapolla, A.2    Odetti, P.3
  • 98
    • 33644698951 scopus 로고    scopus 로고
    • Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes
    • DOI 10.2337/diabetes.54.11.3103
    • Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10 year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with Type 1 diabetes. Diabetes 54, 3103-3111 (2005). (Pubitemid 43334362)
    • (2005) Diabetes , vol.54 , Issue.11 , pp. 3103-3111
    • Genuth, S.1    Sun, W.2    Cleary, P.3    Sell, D.R.4    Dahms, W.5    Malone, J.6    Sivitz, W.7    Monnier, V.M.8
  • 99
    • 23744467295 scopus 로고    scopus 로고
    • Glycation products as markers and predictors of the progression of diabetic complications
    • DOI 10.1196/annals.1333.065
    • Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann. NY Acad. Sci. 1043, 567-581 (2005). (Pubitemid 41123947)
    • (2005) Annals of the New York Academy of Sciences , vol.1043 , pp. 567-581
    • Monnier, V.M.1    Sell, D.R.2    Genuth, S.3
  • 100
    • 76549123888 scopus 로고    scopus 로고
    • Collagen cross-links as a determinant of bone quality: A possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus
    • Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos. Int. 21, 195-214 (2009).
    • (2009) Osteoporos. Int. , vol.21 , pp. 195-214
    • Saito, M.1    Marumo, K.2
  • 102
    • 33644503512 scopus 로고    scopus 로고
    • Collagen glycation and its role in fracture properties of bone
    • Vashishth D. Collagen glycation and its role in fracture properties of bone. J. Musculoskelet. Neuronal Interact. 5, 316 (2005).
    • (2005) J. Musculoskelet. Neuronal Interact. , vol.5 , pp. 316
    • Vashishth, D.1
  • 103
    • 0141997270 scopus 로고    scopus 로고
    • E- carboxymethyllysine are elevated in serum of patients with osteoporosis
    • DOI 10.1093/rheumatology/keg324
    • Hein G, Wiegand R, Lehmann G et al. Advanced glycation end-products pentosidine and N e-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxf.) 42, 1242-1246 (2003). (Pubitemid 37258489)
    • (2003) Rheumatology , vol.42 , Issue.10 , pp. 1242-1246
    • Hein, G.1    Wiegand, R.2    Lehmann, G.3    Stein, G.4    Franke, S.5
  • 105
    • 76549104637 scopus 로고    scopus 로고
    • Urinary levels of pentosidine and the risk of fracture in postmenopausal women: The OFELY study
    • Gineyts E, Munoz F, Bertholon C et al. Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study. Osteoporos. Int. 21, 243-250 (2010).
    • (2010) Osteoporos. Int. , vol.21 , pp. 243-250
    • Gineyts, E.1    Munoz, F.2    Bertholon, C.3
  • 107
    • 2142810972 scopus 로고    scopus 로고
    • Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schönberg disease (type II autosomal dominant osteopetrosis)
    • DOI 10.1373/clinchem.2003.029355
    • Alatalo SL, Ivaska KK, Waguespack SG et al. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type I autosomal dominant osteopetrosis). Clin. Chem. 50, 883-890 (2004). (Pubitemid 38543667)
    • (2004) Clinical Chemistry , vol.50 , Issue.5 , pp. 883-890
    • Alatalo, S.L.1    Ivaska, K.K.2    Waguespack, S.G.3    Econs, M.J.4    Vaananen, H.K.5    Halleen, J.M.6
  • 108
    • 32644460848 scopus 로고    scopus 로고
    • Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease
    • Meier C, Meinhardt U, Greenfield JR et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Pagets disease. Clin. Lab. 52, 1-10 (2006). (Pubitemid 43245859)
    • (2006) Clinical Laboratory , vol.52 , Issue.1-2 , pp. 1-10
    • Meier, C.1    Meinhardt, U.2    Greenfield, J.R.3    De Winter, J.4    Nguyen, T.V.5    Dunstan, C.R.6    Seibel, M.J.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.